Genentech, Inc. Release: Xeloda(R)-Oxaliplatin Combination (XELOX) Shown to Be More Effective Than Standard Chemotherapy Regimen in Adjuvant Colon Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, Inc. announced today that an international Phase III study demonstrated that oral Xeloda® plus oxaliplatin (XELOX) is superior to a commonly used intravenous chemotherapy, 5-FU/LV (infused 5-fluorouracil plus leucovorin), in increasing the time people with adjuvant colon cancer lived without their cancer returning when given immediately after surgery. The data show those who participated in the study and took XELOX immediately after surgery lived longer without their cancer being detectable than those who took intravenous 5U/LV. No new adverse events related to Xeloda were observed in the study.